ASTRAZENECA PLC
AstraZeneca plc () (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Ticker / security symbols
- AZN [1]
- Listing exchanges
- NYSE [1]
- SEC industry
- Pharmaceutical Preparations [1]
- Business sectors
- pharmaceutical industry [2]
- Company / filing name
- ASTRAZENECA PLC [1]
- Headquarters location
- Cambridge; Cambridge Biomedical Campus [2]
- Business address
- 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, CB2 0AA [1]
- Founded
- 1913 [2]
- Legal form
- public limited company [2]
- Incorporation jurisdiction
- United Kingdom [1]
- Leadership in background record
- Pascal Soriot [2]
- Official website
- www.astrazeneca.com ↗ [2]
- Employees
- 70,600 · reported year 2019 [2]
- Annual revenue
- USD 24,384,000,000 · reported year 2019 [2]
- Fiscal year end
- December 31 (SEC record) [1]
- ISIN (reported securities)
- GB0009895292 [2]
- CIK
- 0000901832 [1]
- SIC code
- 2834 [1]
- Country in background record
- United Kingdom; Sweden [2]
Company positioning and business
AstraZeneca plc () (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. [3]
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US. [3]
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Its British counterpart, Zeneca PLC, was formed in 1993 when ICI divested its pharmaceuticals businesses; Astra AB and Zeneca PLC merged six years later, with the chosen headquarters in the United Kingdom. [3]
Background text: Wikipedia contributors, AstraZeneca. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Management and corporate governance
The Wikidata background record identifies Pascal Soriot in the chief-executive role. This background entry is not an official confirmation of the current board or executive roster. [2]
Understanding company scale
Employees: 70,600 · reported year 2019. [2]
Annual revenue: USD 24,384,000,000 · reported year 2019. [2]
Financial year, securities and disclosures
The SEC submissions record gives ASTRAZENECA PLC a fiscal year end of 1231 (MMDD). Individual filings below identify their own reporting period; the filing date is the publication event, not the financial year end. [1]
Listed securities: AZN (NYSE). Multiple symbols may represent different share classes or securities of the same registrant. [4]
History and key events
Financial results and regulatory disclosures
Annual, quarterly and current reports from the collected SEC record. Insider Forms 4 and 144 are excluded. This is a selected list, not a live filing feed.
Source-verified relationships
Companies in the same industry
Comparison candidates share the SEC SIC classification 2834. This does not imply ownership, partnership or trading relationships.
Related entities and concepts
Frequently asked questions
When was ASTRAZENECA PLC founded?
Founded: 1913. The linked source provides the background record. [2]
Where is the headquarters of ASTRAZENECA PLC?
Headquarters location: Cambridge; Cambridge Biomedical Campus. The linked source provides the background record. [2]
Which business sectors are recorded for ASTRAZENECA PLC?
Business sectors: pharmaceutical industry. The linked source provides the background record. [2]
ASTRAZENECA PLC relationship map
Select a node to inspect its relationship and source.
2 verified direct relationships. Industry peers are not relationship edges.
Sources and review dates
- SEC — ASTRAZENECA PLC filing identity and securities ↗
- Wikidata — company background record (CC0) ↗
- Wikipedia contributors — AstraZeneca (CC BY-SA 4.0) ↗
- SEC securities directory ↗
- Company chronology / filing ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.